Tradjenta
utilized to manage type 2 diabetes mellitus to support glycaemic control.
Strengths: 5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Trajenta
- Therapeutic class
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
- Pharmacological class
Gliptin
- Contraindications
hypersensitivity to linagliptin; type 1 diabetes mellitus; diabetic ketoacidosis
- Minor side effects
nasopharyngitis; upper respiratory tract infection; headache
- Moderate side effects
hypoglycaemia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
utilized to manage type 2 diabetes mellitus to support glycaemic control.
- Prescription status
POM
- Manufacturer
Boehringer Ingelheim
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature away from moisture and direct light.
- Drug interactions
rifampicin
- Age restrictions
Not recommended for children and adolescents under 18 years.
Precautions and warnings
monitor for signs of pancreatitis; observe for skin reactions; avoid in patients with severe hepatic impairment
Serious side effects
acute pancreatitis — requires immediate medical attention; bullous pemphigoid — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Mechanism of action
This medication functions as a selective inhibitor of the DPP-4 enzyme. By preventing the breakdown of incretin hormones, it stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner, thereby stabilizing blood sugar levels.
Pregnancy and breastfeeding
Pregnancy: Use is not recommended. Breastfeeding: Discuss benefits and risks with a physician.
Tradjenta
utilized to manage type 2 diabetes mellitus to support glycaemic control.
Editorial Notes
- Active ingredient(s): Linagliptin
- Listed indication(s): Type 2 Diabetes Mellitus
Available option
- 60 tablets - 5 mg1458-5-mg-17609